Taliglucerase alfa

From Wikipedia, the free encyclopedia
Taliglucerase alfa
Clinical data
Legal status ?
Identifiers
ATC code A16AB11
Chemical data
Formula ?
Taliglucerase alfa, commercially known as Elelyso, is a plant-derived enzyme developed by Protalix and Pfizer.[1] The enzyme is a recombinant glucocerebrosidase used to treat Gaucher’s Disease and is the first plant-made pharmaceutical to win approval by the U.S. Food and Drug Administration.[2][3] Expression of proteins in plant cell culture is highly efficient, does not require post-expression modification of the protein, and is not susceptible to contamination by agents such as viruses that are pathological to humans.[4] Using transgenic carrot cells produces a lower cost alternative, and preclinical studies show that the enzyme was well tolerated by patients.[5]

See also

References

  1. ↑ http://clinicaltrials.gov/ct2/show/NCT00962260
  2. ↑ http://www.sciencemag.org/content/320/5875/473.summary
  3. ↑ Maxmen, Amy (2 may 2012) First plant-made drug on the market Nature, Biology & Biotechnology, Industry, Retrieved 26 June 2012
  4. ↑ http://www.gaucherdisease.org/protalix_drug_information.php
  5. ↑ Aviezer, D; Brill-Almon, E; Shaaltiel, Y; Hashmueli, S; Bartfeld, D; Mizrachi, S; Liberman, Y; Freeman, A et al. (2009). "A Plant-Derived Recombinant Human Glucocerebrosidase Enzyme—A Preclinical and Phase I Investigation". In Ho, Paulo Lee. PLoS ONE 4 (3): e4792. doi:10.1371/journal.pone.0004792. PMC 2652073. PMID 19277123. 
Other alimentary tract and metabolism products (A16)
Amino acids and derivatives
Enzymes
Various alimentary tract
and metabolism products

M: DIG

anat (t, g, p)/phys/devp/enzy

noco/cong/tumr, sysi/epon

proc, drug (A2A/2B/3/4/5/6/7/14/16), blte

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.